|HIV-1 drug resistance emergence among breastfeeding infants born to HIV-infected mothers during a single-arm trial of triple-antiretroviral prophylaxis for prevention of mother-to-child transmission: a secondary analysis.|
|Jump to Full Text|
|PMID: 21468304 Owner: NLM Status: MEDLINE|
|BACKGROUND: Nevirapine and lamivudine given to mothers are transmitted to infants via breastfeeding in quantities sufficient to have biologic effects on the virus; this may lead to an increased risk of a breastfed infant's development of resistance to maternal antiretrovirals. The Kisumu Breastfeeding Study (KiBS), a single-arm open-label prevention of mother-to-child HIV transmission (PMTCT) trial, assessed the safety and efficacy of zidovudine, lamivudine, and either nevirapine or nelfinavir given to HIV-infected women from 34 wk gestation through 6 mo of breastfeeding. Here, we present findings from a KiBS trial secondary analysis that evaluated the emergence of maternal ARV-associated resistance among 32 HIV-infected breastfed infants.
METHODS AND FINDINGS: All infants in the cohort were tested for HIV infection using DNA PCR at multiple study visits during the 24 mo of the study, and plasma RNA viral load for all HIV-PCR-positive infants was evaluated retrospectively. Specimens from mothers and infants with viral load >1,000 copies/ml were tested for HIV drug resistance mutations. Overall, 32 infants were HIV infected by 24 mo of age, and of this group, 24 (75%) infants were HIV infected by 6 mo of age. Of the 24 infants infected by 6 mo, nine were born to mothers on a nelfinavir-based regimen, whereas the remaining 15 were born to mothers on a nevirapine-based regimen. All infants were also given single-dose nevirapine within 48 hours of birth. We detected genotypic resistance mutations in none of eight infants who were HIV-PCR positive by 2 wk of age (specimens from six infants were not amplifiable), for 30% (6/20) at 6 wk, 63% (14/22) positive at 14 wk, and 67% (16/24) at 6 mo post partum. Among the 16 infants with resistance mutations by 6 mo post partum, the common mutations were M184V and K103N, conferring resistance to lamivudine and nevirapine, respectively. Genotypic resistance was detected among 9/9 (100%) and 7/15 (47%) infected infants whose mothers were on nelfinavir and nevirapine, respectively. No mutations were detected among the eight infants infected after the breastfeeding period (age 6 mo).
CONCLUSIONS: Emergence of HIV drug resistance mutations in HIV-infected infants occurred between 2 wk and 6 mo post partum, most likely because of exposure to maternal ARV drugs through breast milk. Our findings may impact the choice of regimen for ARV treatment of HIV-infected breastfeeding mothers and their infected infants.
|Clement Zeh; Paul J Weidle; Lillian Nafisa; Humphrey M Lwamba; Jully Okonji; Emily Anyango; Philip Bondo; Rose Masaba; Mary Glenn Fowler; John N Nkengasong; Michael C Thigpen; Timothy Thomas|
Related Documents :
|19208064 - Vitamin d in infants with cystic fibrosis diagnosed by newborn screening.
15352454 - Solar photodecomposition of decabromodiphenyl ether: products and quantum yield.
11749774 - Effects of methylprednisolone and aprotinin on phospholipase d activity of leukocytes i...
10829844 - Metabolic studies in congenital vitamin d deficiency rickets.
15339664 - Endocytosis by random initiation and stabilization of clathrin-coated pits.
3668084 - The effects of maternal mood on mother-infant interaction.
|Type: Clinical Trial; Journal Article; Research Support, U.S. Gov't, P.H.S. Date: 2011-03-29|
|Title: PLoS medicine Volume: 8 ISSN: 1549-1676 ISO Abbreviation: PLoS Med. Publication Date: 2011 Mar|
|Created Date: 2011-04-06 Completed Date: 2011-08-18 Revised Date: 2013-06-30|
Medline Journal Info:
|Nlm Unique ID: 101231360 Medline TA: PLoS Med Country: United States|
|Languages: eng Pagination: e1000430 Citation Subset: IM|
|Division of HIV/AIDS Prevention, US Centers for Disease Control and Prevention, Kisumu, Kenya. email@example.com|
|Data Bank Information|
Bank Name/Acc. No.:
|APA/MLA Format Download EndNote Download BibTex|
Drug Resistance, Viral / drug effects*, genetics
HIV Infections / drug therapy*, prevention & control, transmission*, virology
HIV Seropositivity / virology
HIV-1 / drug effects, genetics, immunology, physiology*
Infectious Disease Transmission, Vertical / prevention & control*
Mutation / genetics
Polymerase Chain Reaction
Viral Load / drug effects
Journal ID (nlm-ta): PLoS Med
Journal ID (publisher-id): PLoS
Journal ID (pmc): plosmed
Publisher: Public Library of Science, San Francisco, USA
This is an open-access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication.
Received Day: 6 Month: 5 Year: 2010
Accepted Day: 17 Month: 2 Year: 2011
collection publication date: Month: 3 Year: 2011
Print publication date: Month: 3 Year: 2011
Electronic publication date: Day: 29 Month: 3 Year: 2011
Volume: 8 Issue: 3
E-location ID: e1000430
PubMed Id: 21468304
Publisher Id: 10-PLME-RA-4900R3
|HIV-1 Drug Resistance Emergence among Breastfeeding Infants Born to HIV-Infected Mothers during a Single-Arm Trial of Triple-Antiretroviral Prophylaxis for Prevention of Mother-To-Child Transmission: A Secondary Analysis Alternate Title:Drug Resistance in Breastfeeding Infants|
|Paul J. Weidle2|
|Humphrey M. Lwamba3|
|Mary Glenn Fowler4|
|John N. Nkengasong5|
|Michael C. Thigpen2¤b|
Role: Academic Editor
1Division of HIV/AIDS Prevention, US Centers for Disease Control and Prevention (CDC), Kisumu, Kenya
2Division of HIV/AIDS Prevention, National Center for HIV, Viral Hepatitis, STD, and TB Prevention, CDC, Atlanta, Georgia, United States of America
3Centre for Global Health Research, Kenya Medical Research Institute, Kisumu, Kenya
4Johns Hopkins Medical Institute, Department of Pathology, Baltimore, Maryland Onsite at Makerere University, Johns Hopkins University Research Collaboration, Kampala, Uganda
5Division of Global HIV/AIDS, Center for Global Health, CDC, Atlanta, Georgia, United States of America
|National Institute of Child Health and Human Development, United States of America
|Correspondence: * E-mail: firstname.lastname@example.org.
Contributed by footnote: ICMJE criteria for authorship read and met: CZ PJW LN HML JO EA PB RM MGF JNN MCT TT. Agree with the manuscript's results and conclusions: CZ PJW LN HML JO EA PB RM MGF JNN MCT TT. Designed the experiments/the study: CZ PJW PB MGF JNN MCT TT. Analyzed the data: CZ PJW LN HML JO EA MCT. Collected data/did experiments for the study: CZ LN HML JO EA PB RM MCT TT. Enrolled patients: RM TT. Wrote the first draft of the paper: CZ PJW. Contributed to the writing of the paper: CZ LN HML JO PB MGF JNN MCT TT. Contributed to the review of the manuscript: EA. Contributed to the study design, responsible for data integrity, reviewed the paper: RM. Participated actively in the original design of the overall Kibs clinical trial including the plan to store samples and analyze for resistance in both mothers and babies; worked with the first author and other coauthors on multiple drafts leading to the current manuscript: MGF.
[current-aff] ¤a: Current address: Family Health International, Nairobi, Kenya
[current-aff] ¤b: Current address: Centers for Disease Control and Prevention-Botswana (CDC-BOTUSA), HIV Prevention Research Unit, Gaborone, Botswana
[current-aff] ¤c: Current address: Centers for Disease Control and Prevention, Arctic Investigations Program, Anchorage, Alaska
Worldwide in 2009, an estimated 370,000 infants acquired HIV infection primarily because of mother-to-child transmission (MTCT) in utero, during the peripartum period, or via breastfeeding ,. MTCT HIV transmission rates range from 25%–40% without antiretroviral medications, 8%–10% when short-course antiretrovirals are given during the peripartum period, and less than 5% when triple-combination maternal antiretroviral therapy is given throughout pregnancy . In sub-Saharan Africa, progress has been made in the last few years toward expanding prevention of mother-to-child transmission (PMTCT) programs with simpler and shorter antiretroviral prophylactic regimens than those used in industrialized countries ,. Additionally, many country guidelines include treatment of eligible HIV-infected pregnant women with triple-combination antiretroviral therapy to improve the mother's health and for PMTCT. More than 95% of HIV-exposed children are born in resource-limited settings where breastfeeding is the norm . Breastfeeding improves overall infant survival, and safe, feasible, and sustainable alternatives to breastfeeding are usually unavailable. According to WHO, breastfeeding in the first 6 mo of life provides 4- to 6-fold protection against mortality as opposed to no breastfeeding –. Early cessation of breastfeeding in an effort to limit the exposure to HIV-infected breast milk may be associated with increased infant morbidity and mortality . The addition of antiretroviral therapy to HIV-infected mothers through the period of breastfeeding is one strategy to reduce HIV transmission via breast milk . The potential mechanisms of protection would include both reduction in maternal viral load in breast milk as well as indirect infant prophylaxis by ingestion of antiretrovirals in breast milk, since several previous studies have shown that antiretroviral drugs (including zidovudine [ZDV], lamivudine [3TC], nevirapine [NVP], and efavirenz) administered to nursing women are present in their breast milk –.
However, the presence of antiretroviral drugs in breast milk may have negative implications for infants who become infected before or during breastfeeding, because of the risk of acquisition of drug resistance caused by viral replication in the presence of low drug concentrations in the infant. To investigate this risk, we evaluated, in a secondary analysis, the emergence of drug resistance among infants born to HIV-infected mothers participating in the Kisumu Breastfeeding Study (KiBS)—a phase IIb PMTCT single-arm non-randomized trial that aimed to assess the safety and transmission rates of a triple-antiretroviral regimen consisting of ZDV, 3TC, and either NVP or nelfinavir (NFV) from 34 wk gestation through 6 mo post partum for PMTCT among HIV-infected breastfeeding mothers . Evaluation of drug levels in the breast milk of a subset of mothers participating in the trial revealed the presence of 3TC and NVP in quantities sufficient to have therapeutic effect on HIV (such as prevention of HIV infection or partial suppression of HIV replication in infected infants and thus potential emergence of HIV drug resistance) . In this secondary analysis, we evaluated the emergence of antiretroviral drug resistance mutations among HIV-infected infants, and ascertained whether resistance mutations developed as a result of exposure to low doses of maternal antiretroviral drugs via breastfeeding or whether they were acquired directly from the mother.
Detailed description of the study design and methods is published . In brief, enrollment was conducted between July 2003 and November 2006; follow-up was completed in February 2009. Women were recruited through the PMTCT programs in the antenatal clinics of the New Nyanza Provincial General Hospital and the Kisumu District Hospital. Pregnant women were invited to enroll if they were HIV positive and if, after receiving risk-benefit counseling on infant-feeding options, they indicated intent to breastfeed (Text S1).
The study intervention consisted of triple-combination maternal antiretroviral therapy (ZDV/3TC and either NVP or NFV) given from 34 wk gestation to 6 mo post partum. Women were instructed to exclusively breastfeed the infants for 5.5 mo and then wean over a 2-wk period with complete cessation of breastfeeding by 6 mo. Women who met World Health Organization (WHO) criteria for combination antiretroviral treatment (either with CD4 count <200/mm3, or WHO stage 3 or 4 HIV disease)  at initiation or subsequently through the study period were continued or reinitiated on antiretroviral therapy during the 24 mo of follow-up. Participants who did not meet treatment criteria had antiretroviral therapy discontinued at 6 mo post partum. Infants were initiated on antiretroviral treatment when they met WHO treatment criteria .
Between July 2003 and January 2005 participants received ZDV 300 mg and 3TC 150 mg in a fixed-dose combination tablet (Combivir, GlaxoSmithKline) taken twice a day and a NVP 200-mg tablet (Viramune, Boehringer Ingelheim) given in an incremental dose from one tablet daily for 2 wk and then one tablet twice a day for the duration of the study ,. Infants received a single 2-mg/kg dose of NVP liquid (Viramune, Boehringer Ingelheim) within 72 h of birth. In January 2005, the protocol was revised because of concerns of an increased risk of symptomatic liver toxicity for women on NVP with CD4>250 cells/µl . Subsequently, participants with CD4≤250 cells/µl received ZDV, 3TC, and NVP as per the previous regimen, and participants with CD4>250 cells/µl received ZDV, 3TC as per the previous regimen and the protease inhibitor (PI), nelfinavir mesylate (NFV) 1,250 mg (as 5×250-mg tablets, Viracept, Hoffman La-Roche Ltd) twice daily.
This study was approved by the Ethical Review Committee of the Kenyan Medical Research Institute as well as the Institutional Review Board of the US Centers for Disease Control and Prevention. Written informed consent was obtained from each participant prior to the study initiation.
Maternal and infant whole blood samples were collected in EDTA-treated anticoagulant vacutainer tubes (Becton Dickinson). Laboratory visits for blood collections were at delivery (between 0 and 7 d of birth), 2, 6, 14 wk, and 6, 9, 12, 18, and 24 mo. Infant HIV-PCR testing was done on dried blood spots using Roche DNA PCR version 1.5 (Roche Diagnostic System). Real-time HIV-PCR evaluation was done at 14 wk, and 6 and 9 mo. For those infants who were HIV-PCR positive, we retrospectively tested the earlier samples to determine the time of first positive HIV-PCR. HIV-1 plasma RNA viral load was quantified from all HIV-infected infant and mothers' specimens at multiple study visits, using the Roche Amplicor HIV-1 monitor version 1.5 (Roche Diagnostic System).
HIV drug resistance mutation analyses of maternal and infant samples were performed using the FDA licensed ViroSeq HIV-1 genotyping system (Applied Biosystems) retrospectively, starting with the week 14 specimens from infants with viral load ≥1,000 copies/ml. For infants with detectable HIV drug resistance mutations at 14 wk, we sequenced the earlier samples (6, 2, and 0 wk) to determine time of first HIV drug resistance mutation. For infants with no HIV drug resistance mutations at 14 wk, we tested specimens at 6 mo. For infants who were first HIV-PCR positive after 14 wk, drug resistance mutation analysis was done on the first HIV-PCR–positive sample.
After genotyping on the ABI 3100 genetic analyzer, sample file analysis was performed by the Sequence analysis software version 3.7 (Applied Biosystems). The 1.5-kb pol region sequences were analyzed with ViroSeq HIV-1 genotyping analysis software version 2.6 to determine HIV drug resistance mutations, as per manufacturer's recommendations. HIV drug resistance mutations were confirmed to be consistent with the Stanford University HIV Drug Resistance Database and categorized according to the International AIDS Society-USA Drug Resistance Mutations Group December 2008 update . To determine the extent of genetic diversity and the influence of specific viral subtype on resistance, the sequences were aligned using the Se-Al multiple sequence alignment program, Phylogenetic Analysis Using Parsimony (PAUP)* 4.0b using HIV reference sequences from GeneBank. HIV-1 inter-subtype recombination was analyzed using SimPlot software 2.0 and further analyzed by constructing a neighbor joining, bootstrapped phylogenetic tree, as implemented in PAUP .
Between July 2003 and November 2006, we enrolled 522 pregnant women who met the eligibility criteria, of whom 21 withdrew and one woman died before delivery. The 500 women delivered 502 live born infants, including nine twin births, one triplet birth, and nine still births. By 24 mo, 32 infants (all singleton births) were HIV positive by PCR test with 24 of the infections having occurred within the first 6 mo of age. Of these 24 infants, 15 were exposed to a maternal NVP-based regimen, whereas nine were exposed to a maternal NFV-based regimen throughout the breastfeeding period (Figure 1). One mother changed regimen at week 14 post delivery from NVP to NFV because of liver toxicity. The rate and risk factors for HIV-MTCT transmissions in the KiBS trial are reported separately .
Among the 12 infants who were first HIV-PCR positive at delivery, we analyzed plasma viral load over the 6-mo breastfeeding period. Median viral load at delivery was 2.8 log copies per ml, decreased ∼3-fold at 2 wk, increased ∼80-fold from 2 wk to 6 wk, and remained between 5 and 6 log copies per ml through 6 mo (Figure 2).
Among the 24 infants who were first HIV-PCR positive by 6 mo (the breastfeeding period), resistance mutations were detected in none of the eight with detectable viral load at delivery or 2 wk (six were not amplifiable), in six (30%) of 20 at 6 wk, in 14 (64%) of 22 at 14 wk, and in 16 (67%) of 24 at 6 mo (Table 1). Of the eight infants who were first HIV-PCR positive after 6 mo (after the intervention period), none developed drug resistance mutations. While only acknowledged by two mothers, continued breastfeeding is the most likely cause of infection after 6 mo. However, none of the eight mothers were taking antiretroviral therapy when the child was first diagnosed HIV-PCR positive.
Of the 24 infants with HIV infection diagnosed by 6 mo, seven of 15 (47%) whose mothers were started on NVP and all nine (100%) of whose mothers were started on NFV, had drug resistance mutations (p = 0.0095, Fisher exact), but the 95% confidence interval for the difference was wide (28%–78%). Among the seven infected infants exposed to maternal NVP who developed resistance mutations, two (71%) had a mutation conferring resistance to only the non-nucleoside reverse-transcriptase inhibitors (NNRTI) class of antiretrovirals, one (14%) had mutations against nucleoside reverse transcriptase inhibitors (NRTI), while four (57%) had multiclass drug resistance against both NRTI and NNRTI drugs. Among the nine HIV-infected infants exposed to maternal NFV, all nine (100%) had an NRTI mutation, but none had a major PI mutation or NNRTI mutation (Table 2).
Of the 12 infants who were HIV-PCR positive at delivery, 11 (92%) infants developed HIV drug resistance mutations by 6 mo. Of the 12 infants who were first HIV-PCR positive from 2 wk to 6 mo of age, five (42%) infants developed HIV drug resistance mutations by 6 mo, and none of the eight infants first positive from 6 to 24 mo developed resistance mutations. Of the 16 infants with HIV drug resistance mutations at 6 mo, 13 (81%) had at least one NRTI resistance mutation (M184 I/V [n = 12], K65R [n = 2], and D67G [n = 1]), and six (38%) had NNRTI resistance mutations (K103N [n = 2], Y181 [n = 2], and G190A [n = 2]) (sequences submitted to GenBank, http://www.ncbi.nlm.nih.gov/Genbank/index.html, accession numbers HM164112-HM164123, HM164127-HM164128, and HM164130-HM164131) (Table 3). No primary PI mutations were detected in any infant.
Phylogenetic analysis of the 32 mother–infant pairs demonstrated subtype distribution as subtype A1 (65.6%), subtype D (9.4%), subtype C (3.1%), and inter-subtype recombinants (21.9%). HIV-1 subtypes among the infants with HIV drug resistance mutations were as follows: 11 (69%) pure subtype A1, one (6%) subtype D, four inter-subtype recombinants (25%). Of the four recombinants, three were circulating recombinant forms (CRFs) A/D and one was CRF D/C. Co-relation between the mother–infant pair sequences was high with bootstrap values of >98% and nucleotide similarity of >97%.
Among the 24 mothers whose infants were first HIV-PCR positive by 6 mo, ten had undetectable viral load (2.6 log copies/ml) at 6 mo post partum and 14 had detectable viral load (median, 3.2 log copies/ml; range 1.7–5.9). Among these 14 women, 10 (71%) had no HIV drug resistance mutations and four (29%) had HIV drug resistance mutations (sequences submitted to GenBank, http://www.ncbi.nlm.nih.gov/Genbank/index.html, accession numbers HM164124-HM164126 and HM164129). Two of the infants born to the four mothers with drug resistance mutations had infections with wild-type strain at first time of positivity, one had HIV drug resistance mutations that differed from that of the mother, and one had overlapping mutation patterns with that of the mother (6.25%) (Table 4). Of the 24 infants first HIV-PCR positive by 6 mo, only two were on antiretrovirals for treatment before 6 mo and both had developed drug resistance mutations before initiation of antiretroviral therapy.
In this study, we investigated the emergence of drug resistance among HIV-infected breastfeeding infants and found that two-thirds of infants who became infected before 6 mo developed resistance to one or more antiretroviral drugs, most likely because of exposure to the drugs through the mother's breast milk. Previous studies have shown that taking antiretroviral therapy while breastfeeding significantly reduces the chances that HIV-infected mothers will transmit the virus to their infants ,,–. However, the infants who get infected (and not put on antiretroviral therapy soon enough or left untreated) may be at risk of developing resistance to some of the antiretroviral drugs the mother is taking. The patterns of HIV viral load in infants and the timing of detection of HIV drug resistance mutations suggests that drug-resistant HIV variants were likely not transmitted. As previously reported by Mirochnick and colleagues , 3TC and NVP given to mothers are transmitted to their infants via breastfeeding in quantities sufficient to have biologic, but suboptimal, effect on HIV with potential risk of emergence of HIV drug resistance . Thus, the HIV drug resistance mutations reported here likely emerged as a result of exposure to antiretroviral drugs ingested by the infant either through single-dose NVP exposure at delivery or indirectly through ingestion of antiretroviral drugs through breast milk. This possibility has also been suggested by the findings of the 6-wk extended NVP study (SWEN) in Uganda, which found the presence of NRTI resistance in infants provided with NVP prophylaxis while the mothers were on a triple-antiretroviral regimen .
Fourteen infants were first HIV-PCR positive by week 2. Only eight of the 14, however, had detectable viral load and none of these had HIV drug resistance mutations detected at the time of diagnosis of HIV infection. The frequency of HIV drug resistance mutations increased over time; 30% of HIV-positive infants developed drug resistance mutations by week 6, 63% by week 14, and 67% by 6 mo. With only one mother–infant pair having similar HIV drug resistance patterns and no cases of HIV drug resistance mutations among the infants first HIV-PCR positive after the mothers discontinued antiretrovirals, there is little evidence to suggest that mothers transmitted resistant HIV to their infants. With single-dose NVP, Eshleman and colleagues  reported a 46% rate of NVP-resistant mutations at 6 wk, and 55% by 12–14 wk, with subsequent waning by 12 mo using standard ViroSeq genotyping techniques. In the present study, where mothers received triple-antiretroviral regimen through 6 mo of breastfeeding and infants chronically ingested suboptimal quantities of antiretroviral drugs via breast milk, there were increased rates of HIV drug resistance mutations in infants at 14 and 24 wk compared to 6 wk, with no evidence of fading of HIV drug resistant mutations. It is most likely that the resistance was maintained over time in the HIV-infected infants because of ongoing exposure to low quantities of antiretroviral drugs in the mother's breast milk.
Our data illustrate a possible relationship between higher viral load in the HIV-infected infants and emergence of drug resistance mutations. The viral load at birth was likely partially suppressed owing to the maternal antiretroviral therapy transferred through the placenta . The decrease in viral load from delivery to 2 wk is presumably due to the single-dose NVP given to all infants at birth and the sharp increase in viral load from 2 wk to 6 wk coincides with the emergence of HIV drug resistance mutations from 6 wk to 6 mo (Figure 2).
Kenyan National guidelines and WHO guidelines for early infant diagnosis recommend testing for HIV at 6 wk . With wide-scale implementation of early infant HIV diagnosis, breastfeeding HIV-infected infants could be started on antiretrovirals different from the maternal antiretrovirals to reduce risk of development of HIV drug resistance and, therefore, lower morbidity and mortality among the HIV-infected infants . It is possible that infection in the first few weeks (not detected by DNA PCR) could still be affected by drug pressure from the infant NVP dose, which could contribute to the observed NVP resistance at 6 wk.
One major limitation in this study was that HIV drug resistance genotyping was performed on maternal plasma samples and not on breast milk, which is a relatively secluded biologic compartment with differences in drug concentrations and may possibly have had drug resistance HIV variants that could be passed to the infants; however, genotypic results from the majority of the infants at the first time of diagnosis revealed the absence of resistant strains. We previously showed that drug concentrations in breast milk and bloodstream differ, and that biologically significant, but suboptimal, amounts of antiretrovirals for treatment of HIV infection could be passed to the infant via breastfeeding . Breast milk concentrations of NVP were ∼70% of maternal plasma levels and in the infants were below the accepted target trough concentration for treatment of HIV. 3TC concentrations were ∼2.5-fold higher in the breast milk than maternal plasma, but below optimal plasma concentrations in the infant. The high proportion of infants developing 3TC resistance mutations in this report is consistent with the sub therapeutic concentrations of 3TC. The relatively low frequency of 3TC resistance among HIV-infected infants exposed to maternal NVP/ZDV/3TC suggests that NVP may be preventing or delaying emergence of 3TC resistance. In contrast, the fact that all HIV-infected infants exposed to maternal NFV/ZDV/3TC developed a 3TC mutation may be explained by possible low levels of NFV in breast milk and consequently low quantities transmitted to the infant . The appearance of K65R in one-quarter of the infants with resistance (Table 3) is of concern, and this might be due to a high level of 3TC in the breast milk ,. A follow-up genotypic analysis on the detection of K65R mutation in breast milk is necessary. ZDV concentrations were very low in breast milk, and, in the infants, were below the limit of quantification most of the time. None of the infants had mutations associated with ZDV resistance, which appears consistent with the low infant plasma ZDV concentrations detected .
All infants in the KiBS trial received single-dose NVP prophylaxis at birth; however, no infants exposed to maternal NFV/ZDV/3TC developed NVP drug resistance mutations. This finding suggests that this maternal regimen provided an effective “tail” with 3TC via breast milk to reduce emergence of NVP drug resistance mutations in the infants during the first few weeks when infant NVP drug levels following single-dose NVP were still present. In contrast, six of 15 infants exposed to both single-dose NVP as well as maternal NVP through breast milk developed at least one NNRTI mutation after 2 wk of age. This finding corroborates other reports that showed that extended infant NVP prophylaxis for PMTCT significantly reduces transmission of HIV to infants ,, but with a high risk of developing resistance to NVP ,. Notably, no infants exposed to maternal NFV developed drug resistance mutations which is consistent with unpublished findings in a subset of women from the KIBS study that NFV and its active metabolite (M8) transfer into breast milk in low concentrations and the resulting concentrations in dried blood spots of their breast-feeding infants for NFV were less than the limit of quantification (LOQ)−30ng/ml, and for M8 <LOQ −32ng/ml [Weidle PJ, personal communication]. In another study, NFV was present in extremely low concentrations in breast milk and M8 was not detected . Others have found no detectable NFV in the plasma of breastfeeding infants whose mothers were taking NFV as part of triple-combination antiretroviral therapy . The subtype distribution observed in this study follow a typical pattern of viruses circulating in this region . Furthermore, we did not observe preferential selection of resistance in these infants based on subtypes.
The WHO recommends exclusive breastfeeding for HIV-exposed infants in resource-limited settings where acceptable, feasible, affordable, sustainable, and where safe replacement feedings cannot be achieved . Owing to this recommendation, there is an urgent need to assess risks and benefits of antiretroviral drugs that are less likely to be transmitted through breast milk, thus reducing risk of exposure of infants to subtherapeutic levels of antiretroviral drugs and hence reducing the risk of development of HIV drug resistance among infants who become HIV infected . The differential development of drug resistance mutations in the infant depending on the maternal antiretroviral regimen may have implications for subsequent treatment options. This tradeoff for low maternal-to-child transmission rates with the use of triple-combination maternal antiretroviral therapy, which includes NVP during breastfeeding, may require more complicated treatment regimens (e.g., including a PI) to treat the small number of infants who do become HIV infected in order to reduce development of drug resistance. However, the options for antiretroviral regimens available in most resource-limited settings are quite limited and so may forestall introduction of ideal combinations that address our findings. Because HIV drug resistance mutations in most infants emerge over time, improvements in early infant HIV diagnosis and treatment programs could mitigate the problem  before drug resistance mutations develop from exposure to maternal antiretrovirals through breastfeeding.
In conclusion, the low mother-to-child HIV transmission rates observed in the KiBS trial support the role of triple-combination maternal antiretroviral therapy as a successful PMTCT intervention among breastfeeding HIV-infected mothers . However, the data from this secondary analysis suggest that ingestion of antiretroviral drugs through breast milk may have contributed to the emergence of HIV drug resistance mutations in the infants, as we observed an increasing frequency of infants with HIV drug resistance mutations over the first 6 mo of life when maternal antiretroviral therapy was given during breastfeeding. Infant drug resistance mutation patterns, depending on the maternal regimen, may have implications for subsequent HIV treatment of the small number of infants, exposed to these maternal regimens, who become HIV infected. Maternal antiretroviral regimens used for PMTCT among HIV-infected breastfeeding women should be evaluated to determine evolution of HIV drug resistance mutations among infants who become HIV infected while exposed to these regimens. PMTCT programs providing maternal antiretroviral therapy during breastfeeding and those caring for infants exposed to antiretroviral through breast milk will need to be cognizant of this issue and consider monitoring these infants more closely and tailoring their treatment accordingly.
(1.24 MB PDF)
Click here for additional data file (pmed.1000430.s001.pdf)
The Academic Editor, Lynne Mofenson, has disclosed that she worked with authors MGF and MCT on other projects unrelated to the study reported in this paper. The authors have no competing interests to declare.
This work was supported by the Kenya Medical Research Institute through a cooperative agreement with the US Centers for Disease Control and Prevention, Grant Award Number-5U19C1000323-05. Study drugs were provided by GlaxoSmithKline and Boehringer Ingelheim. Kenya Medical Research Institute and US Centers for Disease Control and Prevention investigators were involved with all aspects of study design, data collection, and analysis; interpretation of findings; report writing; and decision to submit the manuscript. The findings and conclusions in this article are those of the authors and do not necessarily represent the views of the US Centers for Disease Control and Prevention. Use of trade names is for identification purposes only and does not constitute endorsement by the US Centers for Disease Control and Prevention or the Department of Health and Human Services.
We are grateful to the study participants; the KiBS; the HIV research laboratory; Kenya Medical Research Institute; and Kenya Ministry of Health, whose participation made this study possible. We also thank Glaxo Smith Kline and Boehringer Ingelheim for providing the study medications and Kayla Laserson and Professor Joep MA Lange of the University of Amsterdam for their helpful discussions and critical review of the manuscript. This paper is published with the permission of the Director of KEMRI.
|1.||UNAIDSYear: 2008 Report on the global AIDS epidemic. UNAIDS 2008. Available: http://www.unaids.org/en/media/unaids/contentassets/dataimport/pub/globalreport/2008/jc1511_gr08_executivesummary_en.pdf. Accessed 26 February 2011.|
|2.||Harambat J,Fassinou P,Becquet R,Toure P,Rouet F,et al. Year: 200818-month occurrence of severe events among early diagnosed HIV-infected children before antiretroviral therapy in Abidjan, Cote d'Ivoire: a cohort study.BMC Public Health816918492259|
|3.||Dabis F,Ekpini ER. Year: 2002HIV-1/AIDS and maternal and child health in Africa.Lancet3592097210412086778|
|4.||Wiktor SZ,Ekpini E,Karon JM,Nkengasong J,Maurice C,et al. Year: 1999Short-course oral zidovudine for prevention of mother-to-child transmission of HIV-1 in Abidjan, Cote d'Ivoire: a randomised trial.Lancet35378178510459958|
|5.||Jackson JB,Musoke P,Fleming T,Guay LA,Bagenda D,et al. Year: 2003Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: 18-month follow-up of the HIVNET 012 randomised trial.Lancet36285986813678973|
|6.||UNICEFYear: 2005 Unite for children, unite against AIDS campaign. Available: http://www.unicef.org/aids/index.html. Accessed 26 February 2011.|
|7.||Heinig MJ. Year: 2002Breastfeeding decisions.Pediatrics1101033103412415055|
|8.||Heinig MJ. Year: 2001Host defense benefits of breastfeeding for the infant. Effect of breastfeeding duration and exclusivity.Pediatr Clin North Am4810512311236719|
|9.||Heinig MJ. Year: 1998The American Academy of Pediatrics recommendations on breastfeeding and the use of human milk.J Hum Lact14239543949|
|10.||Nommsen-Rivers L,Heinig MJ. Year: 1997HIV transmission via breastfeeding: reflections on the issues.J Hum Lact131791819341406|
|11.||Moodley D,Moodley J,Coovadia H,Gray G,McIntyre J,et al. Year: 2003A multicenter randomized controlled trial of nevirapine versus a combination of zidovudine and lamivudine to reduce intrapartum and early postpartum mother-to-child transmission of human immunodeficiency virus type 1.J Infect Dis18772573512599045|
|12.||Mirochnick M,Siminski S,Fenton T,Lugo M,Sullivan JL. Year: 2001Nevirapine pharmacokinetics in pregnant women and in their infants after in utero exposure.Pediatr Infect Dis J2080380511734746|
|13.||Mirochnick M,Thomas T,Capparelli E,Zeh C,Holland D,et al. Year: 2009Antiretroviral concentrations in breast-feeding infants of mothers receiving highly active antiretroviral therapy.Antimicrob Agents Chemother531170117619114673|
|14.||Thomas T,Masaba R,Ndivo R,Zeh C,Borkowf C,et al. Year: 2011Triple-antiretroviral prophylaxis to prevent mother-to-child HIV transmission through breastfeeding—The Kisumu Breastfeeding Study, Kenya: A Clinical Trial.PLoS Med8e1001015 doi:10.1371/journal.pmed.1001015.|
|15.||World Health OrganizationYear: 2003Scaling up antiretroviral therapy in resource-limited settings.Treatment guidelines for a public health approachGenevaWHO|
|16.||Mofenson LM,McIntyre JA. Year: 2000Advances and research directions in the prevention of mother-to-child HIV-1 transmission.Lancet3552237224410881908|
|17.||Dorenbaum A,Cunningham CK,Gelber RD,Culnane M,Mofenson L,et al. Year: 2002Two-dose intrapartum/newborn nevirapine and standard antiretroviral therapy to reduce perinatal HIV transmission: a randomized trial.JAMA28818919812095383|
|18.||United States Food and Drug AdministrationYear: 2005 Public health advisory for nevirapine (Viramune). Available: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/PublicHealthAdvisories/ucm051674.htm. Accessed 26 February 2011.|
|19.||Johnson VA,Brun-Vezinet F,Clotet B,Gunthard HF,Kuritzkes DR,et al. Year: 2008Update of the drug resistance mutations in HIV-1: spring 2008.Top HIV Med16626818441382|
|20.||Swofford DL. Year: 2001PAUP: Phylogenetic analysis using parsimony, version 4.Sunderland (Massachusetts)Sinauer|
|21.||Lidstrom J,Guay LA,Musoke P,Owor M,Onyango-Makumbi C,et al. Year: 2010Multi-class drug resistance arises frequently in hiv-infected breastfeeding infants whose mothers initiate highly active antitetroviral therapy (HAART) post-partum [Abstract].The 17th Conference on Retroviruses and Opportunistic Infections; 16-19 February 2010; San Francisco (California, United States)|
|22.||Eshleman SH,Mracna M,Guay LA,Deseyve M,Cunningham S,et al. Year: 2001Selection and fading of resistance mutations in women and infants receiving nevirapine to prevent HIV-1 vertical transmission (HIVNET 012).AIDS151951195711600822|
|23.||World Health OrganizationYear: 2007 HIV transmission through breastfeeding; a review of available evidence; an update from 2001 to 2007. Available: http://whqlibdoc.who.int/publications/2008/9789241596596_eng.pdf. Accessed 26 February 2011.|
|24.||Violari A,Cotton MF,Gibb DM,Babiker AG,Steyn J,et al. Year: 2008Early antiretroviral therapy and mortality among HIV-infected infants.N Engl J Med3592233224419020325|
|25.||Corbett A,Martinson F,Rezk N,Kashuba A,Jamieson D,et al. Year: 2008Antiretroviral drug concentrations in breastmilk and breastfeeding infants.The 15th Conference on Retroviruses and Opportunistic Infections; 3–6 February 2008; Boston (Massachusetts, United States)CROI 2008|
|26.||Kumwenda NI,Hoover DR,Mofenson LM,Thigpen MC,Kafulafula G,et al. Year: 2008Extended antiretroviral prophylaxis to reduce breast-milk HIV-1 transmission.N Engl J Med35911912918525035|
|27.||Moorthy A,Gupta A,Sastry J,Venkatramani V,Bbosale R,et al. Year: 2008Timing of infection is critical for nevirapine resistance outcomes among breastfed subtype C HIV-1 infected infants exposed to extended vs single-dose NVP prophylaxis: The India SWEN Study [Abstract 44, 86 2008].The 15th Conference on Retroviruses and Opportunistic Infections; 3–6 February 2008; Boston (Massachusetts, United States)|
|28.||Church JD,Omer SB,Guay LA,Huang W,Lidstrom J,et al. Year: 2008Analysis of nevirapine (NVP) resistance in Ugandan infants who were HIV infected despite receiving single-Dose (SD) NVP versus SD NVP plus daily NVP up to 6 weeks of age to prevent HIV vertical transmission.J Infect Dis1981075108218684096|
|29.||Colebunders R,Hodossy B,Burger D,Daems T,Roelens K,et al. Year: 2005The effect of highly active antiretroviral treatment on viral load and antiretroviral drug levels in breast milk.AIDS191912191516227801|
|30.||Yang C,Li M,Shi YP,Winter J,van Eijk AM,et al. Year: 2004Genetic diversity and high proportion of intersubtype recombinants among HIV type 1-infected pregnant women in Kisumu, western Kenya.AIDS Res Hum Retroviruses2056557415186532|
|31.||World Health OrganizationYear: 2007 HIV and Infant feeding Update. Available: http://whqlibdoc.who.int/publications/2007/9789241595964_eng.pdf. Accessed 28 February 2011.|
|KiBS||Kisumu Breastfeeding Study|
|NNRTI||non-nucleoside reverse-transcriptase inhibitor|
|NRTI||nucleoside reverse transcriptase inhibitor|
|PMTCT||prevention of mother-to-child transmission|
Table 1 HIV-1 drug resistance emergence among breastfeeding infants in the Kisumu Breastfeeding (KiBS) trial, Kenya, 2003–2008.
|Visit||First HIV-PCR Positive||Samples with Resistance (n)/Samples Tested (n)|
|0–2 wk||6 wk||14 wk||6 mo||>6 mo|
Age refers to scheduled visit age at which samples were obtained.
Table 2 HIV drug resistance mutations among breastfeeding infants at 6 mo post partum according to maternal regimen.
|HIV Drug Resistance Mutations||Maternal Antiretroviral Therapy Regimen|
|ZDV, 3TC, NVP (n = 287)||ZDV, 3TC, NFV (n = 200)|
|HIV-PCR positive by 6 mo||15||9|
|Total with HIV drug resistance mutations||7||9|
One mother was originally taking NVP/ZDV/3TC, but was changed to NFV/ZDV/3TC at week 14.
Table 3 HIV drug resistance mutation patterns among breastfeeding infants at time of emergence.
|Infant Number||Mother's Regimen||Time of First Positive HIV-PCR||Time of Resistant Emergence||Mutations at Emergence||Subtypes|
|1-0079-3||NVP/ZDV/3TC||0–1 wk||6 wk||Y181C + G190A||A/D|
|1-0195-6||NVP/ZDV/3TC||0–1 wk||6 mo||K103KN||A|
|1-0212-2||NVP/ZDV/3TC||6 mo||6 mo||Y181C||A|
|1-0230-2||NVP/ZDV/3TC||0–1 wk||14 wk||M184V||D/C|
|1-0472-8||NVP/ZDV/3TC||0–1 wk||14 wk||K65R, M184V, K103N, Y181C||A|
|1-0066-8||NVP/ZDV/3TC||0–1 wk||14 wk||K65R + D67G + G190A||A|
|1-0317-8||NVP/ZDV/3TC||14 wk||14 wk||M184I +Y181C||D|
|1-0289-1||NFV/ZDV/3TC||2 wk||14 wk||M184V||A|
|1-0410-4||NFV/ZDV/3TC||6 wk||6 wk||M184I/V||A/D|
|1-0357-5||NFV/ZDV/3TC||0–1 wk||14 wk||M184V||A|
|1-0457-9||NFV/ZDV/3TC||0–1 wk||6 wk||K65R + M184V||A|
|1-360-0||NFV/ZDV/3TC||0–1 wk||6 wk||M184V||A|
|1-0437-5||NFV/ZDV/3TC||14 wk||14 wk||M184I||A|
|1-0496-6||NFV/ZDV/3TC||0–1 wk||6 wk||K65R + M184V||A|
|1-0517-4||NFV/ZDV/3TC||0–1 wk||14 wk||M184V||A|
|1-0278-8||NFV/ZDV/3TC||0–1 wk||14 wk||M184V||A/D|
Table 4 Comparison of infant and maternal HIV drug resistance mutation patterns by 6 mo.
|Infant Number||HIV Drug Resistance Mutations|
|0–0472||M184V||K103N||M184V, K65R||K103N, Y181C|
Previous Document: Enzymatic blockade of the ubiquitin-proteasome pathway.
Next Document: Ubiquitylation in ERAD: reversing to go forward?